Iguratimod PCD Pharma Franchise Company
Cafoli Lifecare offers an Iguratimod tablet for PCD pharma franchise and third-party manufacturing. It is produced in WHO-GMP certified facilities, giving distributors a newer disease-modifying option for the rheumatology segment.
What is Iguratimod?
Iguratimod is a small-molecule disease-modifying antirheumatic drug (DMARD). It suppresses the production of inflammatory cytokines and immunoglobulins, reducing joint inflammation and slowing disease progression in rheumatoid arthritis. See PubChem for chemical and pharmacological data.
Therapeutic Applications
Iguratimod is used to treat rheumatoid arthritis, either alone or in combination with methotrexate, to control inflammation and protect joints. It is prescribed chiefly by rheumatologists and consultant physicians.
Why Iguratimod is a High-Potential Molecule for Distributors
Iguratimod is a relatively new DMARD with growing use in rheumatoid arthritis, and it currently faces limited competition in the Indian PCD segment. Because RA therapy continues for years with high adherence, early franchise partners can secure a differentiated, specialist-driven molecule with strong repeat potential before it becomes crowded.
Why Choose Cafoli Lifecare
Cafoli Lifecare supports partners with monopoly PCD rights, WHO-GMP manufacturing, DCGI-approved formulations, complete promotional inputs and a network of 1000+ franchise partners across India.
References
- PubChem – Iguratimod
- PubMed – Iguratimod in rheumatoid arthritis
Our formulations of Iguratimod find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: